RPRX Stock Summary and Trading Ideas (Royalty Pharma PLC - Class A | NASDAQ:RPRX)

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Royalty Pharma PLC - Class A trades on the NASDAQ stock market under the symbol RPRX.

As of January 6, 2025, RPRX stock price declined to $25.75 with 2,107,172 million shares trading.

RPRX has a beta of 0.07, meaning it tends to be less sensitive to market movements. RPRX has a correlation of 0.00 to the broad based SPY ETF.

RPRX has a market cap of $11.44 billion. This is considered a Large Cap stock.

Last quarter Royalty Pharma PLC - Class A reported $565 million in Revenue and $1.04 earnings per share. This fell short of revenue expectation by $-131 million and exceeded earnings estimates by $.11.

In the last 3 years, RPRX traded as high as $44.75 and as low as $24.05.

The top ETF exchange traded funds that RPRX belongs to (by Net Assets): VTI, VO, VXF, VTV, VOE.

RPRX has underperformed the market in the last year with a return of -3.2%, while the SPY ETF gained +28.7%. In the last 3 month period, RPRX fell short of the market, returning -6.5%, while SPY returned +4.2%. However, in the most recent 2 weeks RPRX has outperformed the stock market by returning +2.0%, while SPY returned +0.1%.

RPRX support price is $25.47 and resistance is $26.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RPRX shares will trade within this expected range on the day.